Loading
Cullinan Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Lynx1 Capital Management LP, was filed 30 Oct 2025.
Insider Decl.
297
Thresholds
n/a
Buy Volume
€40M
24 ops. · all time
Sell Volume
€26M
165 ops. · all time
Who traded when
BuySaleJennifer Michaelson21 sales
Lynx1 Capital Management LP8 buys
Jacquelyn L. Sumer5 sales
Jeffrey Alan Jones5 sales
Nadim Ahmed5 sales
Mary Kay Fenton1 sale
Since the insiders bought
- +73.8%Entry US$8.66 · Close 21 Oct 2026 US$15.05
- +8.5%Entry US$12.08 · Close at T+365 US$13.11
- -5.1%Entry US$12.28 · Close at T+365 US$11.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Cullinan Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$33.45.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$14.83
Analyst consensus
11 analystsStrong buy
US$23.00Target US$33.45(+126%)US$42.00
Income statement
EBITDA-US$241.3M
Net income-US$219.9M0.0% margin
Valuation
PER (forward)-5.9x
P/Book3.0x
Beta-0.04
Balance sheet & cash
Market capUS$954.4M
Total debtUS$2.7M
Free Cash Flow-US$175.8M
Debt / Equity1%
Profitability & ownership
ROE-50.3%
ROA-31.4%
% insiders0.4%
% institutions112.5%
Last declaration on 10 September 2026
Declarations297 total
4,000 shares@ US$4.300.0017% mcap0.3% of flowCommon StockSEC:0001193125-26-387381:0
8,000 shares@ US$21.570.017% mcap3.1% of flowCommon StockSEC:0001193125-26-387381:1
8,000 shares@ US$22.090.018% mcap19.3% of flowCommonSEC144:0001950047-26-009190
30,000 shares@ US$4.300.013% mcap5.7% of flowCommon StockSEC:0001193125-26-352523:0
30,000 shares@ US$20.260.063% mcap27.1% of flowCommon StockSEC:0001193125-26-352523:1
30,000 shares@ US$19.600.061% mcap64.9% of flowCommonSEC144:0001950047-26-008087
4,000 shares@ US$4.300.0018% mcap0.8% of flowCommon StockSEC:0001193125-26-297605:0
8,000 shares@ US$17.820.015% mcap6.4% of flowCommon StockSEC:0001193125-26-297605:1
8,000 shares@ US$17.630.015% mcap15.7% of flowCommonSEC144:0001950047-26-006865
8,000 shares@ US$15.682.3% of flowCommon StockSEC:0001193125-26-098781:1
4,000 shares@ US$4.300.8% of flowCommon StockSEC:0001193125-26-098781:0
1,780 shares@ US$14.141.1% of flowCommon StockSEC:0001193125-26-077259:0
3,601 shares@ US$14.470.9% of flowCommon StockSEC:0001193125-26-072002:1
13,515 shares@ US$14.4726.0% of flowCommon StockSEC:0001193125-26-072001:0
4,582 shares@ US$14.4723.2% of flowCommon StockSEC:0001193125-26-072000:0
1,752 shares@ US$13.991.1% of flowCommon StockSEC:0001193125-26-072002:0
3,601 shares@ US$14.4723.9% of flowCommon StockSEC:0001193125-26-071997:0
8,000 shares@ US$4.300.6% of flowCommon StockSEC:0001193125-26-064256:1
8,000 shares@ US$14.302.0% of flowCommon StockSEC:0001193125-26-064256:2
4,398 shares@ US$13.6299.7% of flowCommon StockSEC:0001193125-26-064261:0
4,982 shares@ US$13.6223.8% of flowCommon StockSEC:0001193125-26-064257:0
3,742 shares@ US$13.622.2% of flowCommon StockSEC:0001193125-26-064256:0
3,742 shares@ US$13.6223.5% of flowCommon StockSEC:0001193125-26-064255:0
16,381 shares@ US$13.6229.7% of flowCommon StockSEC:0001193125-26-064254:0
68,750 shares0Common StockSEC:0001193125-26-059637:0
25 of 297 declarations
About Cullinan Therapeutics, Inc.
On January 12, 2021, 5 filers bought EUR 13,897,019 worth at Cullinan Therapeutics, Inc. (Health Care): UBS Oncology Impact Fund L.P., a holder of more than 10%, and director Ansbert Gadicke each filed EUR 5,180,622. BVF Partners L P/il bought EUR 4,739,662 on May 12, 2022. The 25 purchases total EUR 45,597,478 (median EUR 1,194,400), or 12% of open-market trades, with 7 cluster-buy filings.
The 183 sales are smaller: EUR 31,461,016 in all, with a median of EUR 50,896. Vision SCS F2 sold EUR 2,353,261 on May 12, 2022, and Ansbert Gadicke as well as UBS Oncology Impact Fund L.P. EUR 1,322,556 each on August 23, 2021.
Read moreShow less
Of 297 filings from 20 filers, 37 are grants, 27 are option exercises and 25 are of another kind. Jennifer Michaelson (Chief Scientific Officer) files 72, of which 49 sales, Ansbert Gadicke 44 and Jeffrey Trigilio (Chief Financial Officer) 22. The year 2021 has 110 filings. The last twelve months hold 38, of which 1 purchase and 26 sales. Insiders hold 0.4% of the capital, valued at USD 954.4 million. The 25 purchases tracked at 90 days show a median of 17.5% with 100% of cases positive, recorded past results, not a forecast.
